Nov 10 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
PROVIDES CORPORATE UPDATES
* REVENUES FOR THREE MONTHS ENDED SEPTEMBER 30, 2022, WERE
ABOUT
$4.9 MILLION, COMPARED TO ABOUT $1.6 MILLION FOR THREE MONTHS
ENDED JUNE 30, 2022
* QTRLY LOSS PER SHARE $0.51
* Q3 EARNINGS PER SHARE VIEW $-0.64, REVENUE VIEW $972000.00
--
REFINITIV IBES DATA
* ARAVIVE - CONTINUED ADVANCEMENT OF CLINICAL TRIALS IN
PLATINUM
RESISTANT OVARIAN CANCER, CLEAR CELL RENAL CELL CARCINOMA,
PANCREATIC ADENOCARCINOMA
Source text for Eikon: ID:nGNX4p0Mvd
Further company coverage: ARAV.O
((Reuters.Briefs@thomsonreuters.com;))